Exelixis recently announced its impressive first-quarter earnings for 2025, with revenue and net income showing substantial growth. This financial performance, coupled with the FDA approval of CABOMETYX for new indications, likely contributed to the company's 12.65% share price increase over the last quarter. The company's share repurchase program announcement also adds potential upward pressure, reflecting confidence in its future prospects. Given the broader market's 12% annual increase and recent 4% rise, Exelixis's price movement aligns well with overall market trends, with its strong earnings and strategic product advancements adding supportive momentum.

Be aware that Exelixis is showing 1 possible red flag in our investment analysis.NasdaqGS:EXEL Earnings Per Share Growth as at May 2025

This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality.

Exelixis's recent FDA approval and strong earnings performance have set a bullish investors' narrative, aligning with analysts' positive projections for revenue and earnings growth. Over the past three years, the company's total shareholder return was very large at 78.59%, indicating strong historical performance. In comparison, over the past year, Exelixis's stock outperformed the US Market, which returned 11.5%. This past performance suggests resiliency and an ability to drive growth, factors that may further encourage investor confidence as the company expands its cabozantinib indications and accelerates its Phase I pipeline development.

The approval and increased indications of CABOMETYX, combined with potential revenue growth driven by new oncology franchises, could significantly enhance Exelixis's revenue and earnings projections. Analysts forecast a revenue increase of 9.7% annually, with earnings expected to reach US$943 million by 2028. These developments support the recent strategic decisions, such as the share repurchase program, which may positively impact earnings per share by reducing outstanding shares. The current share price of US$36.86 shows a marginal discount of approximately 3.1% to analysts' consensus price target of US$38.05, reflecting market confidence in Exelixis being fairly valued at present. These projections underline the company's ambition to solidify its market position while highlighting underlying business challenges such as rising costs and competitive pressures.

Assess Exelixis' future earnings estimates with our detailed growth reports.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Story Continues

Companies discussed in this article include NasdaqGS:EXEL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments